U.S. top court declines to hear patent case on glaucoma drug
WASHINGTON, March 31
WASHINGTON, March 31 (Reuters) - The U.S. Supreme Court on Monday left intact an appeals court ruling that endorsed patent protections for Combigan, Allergan Inc's glaucoma drug.
The high court declined to hear an appeal filed by Novartis AG's Sandoz Inc, which had challenged several patents held by Allergan that do not expire until 2022. Sandoz wanted to sell a generic version of the drug, which also is used to treat ocular hypertension.
In May 2013, the U.S. Court of Appeals for the Federal Circuit decision ruled in favor of Allergan.
The case is Sandoz v. Allergan, U.S. Supreme Court, 13-889. (Reporting by Lawrence Hurley; Editing by Howard Goller and Alden Bentley)
- China food scandal spreads, drags in Starbucks, Burger King and McNuggets in Japan |
- Court deals blow to Obama health law by limiting subsidies
- Israel pounds Gaza despite international peace efforts |
- Train carrying MH17 bodies on final journey reaches Ukraine city |
- EU readies capital, tech sanctions on Russia, but not yet